Macrolide resistance in mycoplasma genitalium is strongly associated with STI co-infection

Background Co-infections can compromise empirical therapy when treating genital discharge syndrome (GDS). In the UK, lack of testing for Mycoplasma genitalium (MG), a common cause of GDS, is particularly challenging because of increasing rates of macrolide antimicrobial resistance (AMR). We calculated prevalence of MG co-infections, macrolide resistance and associated risk factors in a diverse symptomatic sexual health clinic (SHC) population. Methods SHC attendees in England aged ≥16 years, symptomatic of an STI provided: vulvovaginal swabs (females), first void urine (men-who-have-sex-with-women (MSW) and men-who-have-sex-with-men (MSM)), pharyngeal and rectal swabs (MSM). Routine clinic Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) results were obtained and PCR used for MG detection. Macrolide resistance was determined using Sanger sequencing. Unadjusted and risk factor adjusted odds ratios (ORs) for being MG resistant were derived using logistic regression models. Results Prevalence of MG was 9.5% across all groups and 6.5%(95%CI:4.6–8.9), 12.8%(9.1–17.3) and 12.3%(8.5–17.1) in females, MSW and MSM, respectively (p Conclusion Having an STI co-infection with MG was the strongest indicator of likelihood of having macrolide resistance which was also associated with being in particular risk groups. These findings are suggestive that macrolide resistance may be maintained in discreet sexual networks that are themselves exposed to antibiotic selection pressures. Disclosure No significant relationships.